You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

121 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
DOXOrubicin,
vinCRIStine,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2018
Guidelines and Advice
Status: Current
May 2018
Cancer facts
Aug 2018
Guidelines and Advice
Status: Current
ID: ES SMG-2
Jun 2018
Guidelines and Advice
Status: Current
ID: GL END 2-31
Jul 2018
Guidelines and Advice
Status: Current
Version: 1
Jun 2018
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Drugs Used:
CISplatin,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2018
Cancer facts
Sep 2018
Cancer facts
Oct 2018
Guidelines and Advice
Status: Education and Information
Version: 1
Mar 2018
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
chlorambucil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2018
Cancer facts
Nov 2018

Pages